Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares Outstanding
Ratios

Aligos Therapeutics (ALGS) Shares Outstanding (2020 - 2025)

Aligos Therapeutics filings provide 6 years of Shares Outstanding readings, the most recent being $6.2 million for Q4 2025.

  • On a quarterly basis, Shares Outstanding rose 59.87% to $6.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $6.2 million, a 59.87% increase, with the full-year FY2025 number at $6.2 million, up 59.87% from a year prior.
  • Shares Outstanding hit $6.2 million in Q4 2025 for Aligos Therapeutics, roughly flat from $6.2 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $42.9 million in Q1 2023 to a low of $1.7 million in Q4 2022.
  • Median Shares Outstanding over the past 5 years was $6.2 million (2025), compared with a mean of $19.0 million.
  • Biggest five-year swings in Shares Outstanding: tumbled 95.98% in 2022 and later soared 102.03% in 2025.
  • Aligos Therapeutics' Shares Outstanding stood at $42.7 million in 2021, then tumbled by 95.98% to $1.7 million in 2022, then soared by 74.96% to $3.0 million in 2023, then rose by 28.65% to $3.9 million in 2024, then soared by 59.87% to $6.2 million in 2025.
  • The last three reported values for Shares Outstanding were $6.2 million (Q4 2025), $6.2 million (Q3 2025), and $6.2 million (Q2 2025) per Business Quant data.